Skip to content

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Library

By pinki shah / May 14, 2022

Speciality

Author / Speaker

Title of Presentation

Type of Media

Event

2024 Event

Clear

Displaying 1,051 - 1,075 of 2,711

«
1
…
41
42
43
44
45
…
109
»

Management of Immune Related Adverse Events

Management of Immune Related Adverse Events

By: Mary I. Carroll, DNP, FNP-C, OCN

Management of Immune Related Adverse Events

Management of Immune Related Adverse Events

By: Mary I. Carroll, DNP, FNP-C, OCN

Immunotherapy Updates in Breast Cancer

Immunotherapy Updates in Breast Cancer

By: Maryam Lustberg, MD

Toxicities in Immunotherapy

Toxicities in Immunotherapy

By: Mayra A. Lima, ARNP, MSN, FNP-C

Toxicities in Immunotherapy

Toxicities in Immunotherapy

By: Mayra A. Lima, ARNP, MSN, FNP-C

What To Do When Patients Getting Immunotherapy Do Not Respond to Steroids (Hepatitis, Colitis, Pneumonitis, and Others)

What To Do When Patients Getting Immunotherapy Do Not Respond to Steroids (Hepatitis, Colitis, Pneumonitis, and Others)

By: Mayra Lima, ARNP

What To Do When Patients Getting Immunotherapy Do Not Respond to Steroids
(Hepatitis, Colitis, Pneumonitis, and Others)

What To Do When Patients Getting Immunotherapy Do Not Respond to Steroids (Hepatitis, Colitis, Pneumonitis, and Others)

By: Mayra Lima, ARNP

Optimizing Immunotherapy with Radiation

Optimizing Immunotherapy with Radiation

By: Megan Daly, MD

Car-T Cells and other Cellular Based Therapies

Car-T Cells and other Cellular Based Therapies

By: Mehrdad Abedi (UCD)

Immunotherapy Session

Immunotherapy Session

By: Michael Hurwitz, MD, PhD, Sanjiv Agarwala, MD,

Advances in Non-PD(L)1 Immunotherapies

Advances in Non-PD(L)1 Immunotherapies

By: Miguel Villalona-Calero

Advances in Non-PD(L)1 Immunotherapies

Advances in Non-PD(L)1 Immunotherapies

By: Miguel Villalona-Calero

Advances in Non-PD(L)1 Immunotherapies in Solid Tumors

Advances in Non-PD(L)1 Immunotherapies in Solid Tumors

By: Miguel Villalona-Calero, MD

Chimeric Antigen Receptor T-cell therapy in 2020: Current Indications

Chimeric Antigen Receptor T-cell therapy in 2020: Current Indications

By: Mohamed A. Kharfan-Dabaja, MD, MBA, FACP

Advances in Car-T Cells Development for Cancer Therapy

Advances in Car-T Cells Development for Cancer Therapy

By: Mohamed Abou-el-Enein, MD, PhD, MSPH

Advances in Car-T Cells Development for Cancer Therapy

Advances in Car-T Cells Development for Cancer Therapy

By: Mohamed Abou-el-Enein, MD, PhD, MSPH

Advances in Cellular Therapies for Cancer

Advances in Cellular Therapies for Cancer

By: Mohamed Abou-el-Enein, MD, PhD, MSPH

Chimeric Antigen Receptor T-Cell Therapy: Indications and Remaining Challenges

Chimeric Antigen Receptor T-Cell Therapy: Indications and Remaining Challenges

By: Mohamed Kharfan-Dabaja, MD

Updates in CAR T Therapies

Updates in CAR T Therapies

By: Naseem Esteghamat, MD

Updates in CAR-T Therapies

Updates in CAR-T Therapies

By: Naseem Esteghamat, MD, MS

Updates in CAR-T Therapies

Updates in CAR-T Therapies

By: Naseem Esteghamat, MD, MS

Immunotherapy and Exciting Updates in Advanced Prostate Cancer

Immunotherapy and Exciting Updates in Advanced Prostate Cancer

By: Natalie Reizine, MD

Keynote Lecture: CAR-T Cell and Cellular Therapy Update

Keynote Lecture: CAR-T Cell and Cellular Therapy Update

By: Navneet Majhail, MD, MS, FASTCT

Keynote Lecture: CAR-T Cell and Cellular Therapy Update

Keynote Lecture: CAR-T Cell and Cellular Therapy Update

By: Navneet Majhail, MD, MS, FASTCT

Immunotherapy for Gynecology-Oncology Malignancies: Is There Still Time for Progress?

Immunotherapy for Gynecology-Oncology Malignancies: Is There Still Time for Progress?

By: Oladap O. Yeku, MD, PhD, FACP

«
1
…
41
42
43
44
45
…
109
»

Post navigation

← Previous View

© 2024 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok